Morgan Stanley has filed a registration statement for a new biotech fund with the Securities and Exchange Commission.

The Morgan Stanley Biotechnology Fund will invest 80% of its assets in biotech companies with a market capitalization of less than $1 billion, according to the filing. As much as 15% of the remaining assets would be invested in securities below the investment grade. The product will be managed by Morgan Stanley Investment Advisors.

The fund will carry a load of 5.25% according to the SEC document.

Morgan Stanley officials could not be reached at press time.

Subscribe Now

Access to premium content including in-depth coverage of mutual funds, hedge funds, 401(K)s, 529 plans, and more.

3-Week Free Trial

Insight and analysis into the management, marketing, operations and technology of the asset management industry.